X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2042) 2042
Book Review (495) 495
Publication (226) 226
Book Chapter (47) 47
Conference Proceeding (13) 13
Dissertation (5) 5
Magazine Article (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1443) 1443
brutons tyrosine kinase (1098) 1098
humans (979) 979
animals (747) 747
bruton's tyrosine kinase (620) 620
immunology (593) 593
mice (488) 488
x-linked agammaglobulinemia (420) 420
biochemistry & molecular biology (393) 393
signal transduction (371) 371
activation (357) 357
tyrosine (330) 330
protein-tyrosine kinases - metabolism (303) 303
btk (298) 298
protein-tyrosine kinases - genetics (291) 291
hematology (280) 280
ibrutinib (279) 279
male (270) 270
phosphorylation (270) 270
mutation (260) 260
oncology (254) 254
cell biology (253) 253
bruton tyrosine kinase (234) 234
chronic lymphocytic-leukemia (221) 221
kinases (213) 213
female (202) 202
protein-tyrosine kinase (199) 199
b-lymphocytes - immunology (198) 198
expression (198) 198
proteins (183) 183
protein-tyrosine kinases - antagonists & inhibitors (182) 182
lymphocytes b (174) 174
nf-kappa-b (173) 173
abridged index medicus (171) 171
cancer (166) 166
leukemia (163) 163
agammaglobulinemia - genetics (158) 158
hemic and lymphatic diseases (155) 155
lymphoma (152) 152
apoptosis (145) 145
article (141) 141
b-lymphocytes - metabolism (136) 136
b cells (132) 132
lymphomas (131) 131
molecular sequence data (129) 129
b-cell receptor (124) 124
amino acid sequence (121) 121
receptor (117) 117
receptors, antigen, b-cell - metabolism (116) 116
research (116) 116
cell line (113) 113
bruton’s tyrosine kinase (110) 110
mice, inbred c57bl (109) 109
mice, knockout (109) 109
agammaglobulinemia (108) 108
pharmacology & pharmacy (108) 108
phosphatidylinositol 3-kinase (108) 108
analysis (107) 107
leukemia, lymphocytic, chronic, b-cell - drug therapy (107) 107
protein kinase inhibitors - pharmacology (107) 107
adult (104) 104
chronic lymphocytic leukemia (104) 104
ph domain (103) 103
brutons-tyrosine-kinase (100) 100
signal-transduction (100) 100
cells (99) 99
gene expression (99) 99
lymphocytes (98) 98
protein (97) 97
pyrimidines - therapeutic use (95) 95
medicine, research & experimental (93) 93
signal transduction - immunology (93) 93
patients (92) 92
antigen receptor (91) 91
inhibitors (90) 90
child (89) 89
mantle cell lymphoma (89) 89
protein-tyrosine kinases - chemistry (89) 89
pyrazoles - therapeutic use (89) 89
gene (88) 88
pleckstrin homology domain (88) 88
protein binding (88) 88
immunodeficiency (87) 87
signal transduction - drug effects (87) 87
flow cytometry (86) 86
genetic aspects (85) 85
protein kinase inhibitors - therapeutic use (85) 85
protein structure, tertiary (85) 85
chronic lymphatic leukemia (84) 84
inflammation (84) 84
pyrimidines - pharmacology (84) 84
immune system diseases (83) 83
agammaglobulinaemia tyrosine kinase (82) 82
pci-32765 (82) 82
cells, cultured (81) 81
toll-like receptors (81) 81
cell line, tumor (80) 80
multidisciplinary sciences (80) 80
in-vivo (79) 79
biophysics (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2055) 2055
Chinese (7) 7
French (6) 6
Japanese (5) 5
Korean (5) 5
Spanish (3) 3
German (2) 2
Czech (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 24, pp. 2286 - 2294
Journal Article
Blood, ISSN 0006-4971, 06/2011, Volume 117, Issue 23, pp. 6287 - 6296
B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) is essential to BCR signaling and... 
B-CELLS | CLL | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | APOPTOTIC CELL-DEATH | RITUXIMAB | SURVIVAL SIGNALS | LYMPHOMA | DRUG-RESISTANCE | INHIBITOR | HEMATOLOGY | EXPRESSION | T-Lymphocytes - enzymology | Apoptosis - drug effects | Humans | Tumor Necrosis Factor-alpha - genetics | Cell Survival - genetics | Apoptosis - genetics | Male | NF-kappa B - metabolism | Neoplasm Proteins - antagonists & inhibitors | Receptors, Antigen, B-Cell - metabolism | Mitogen-Activated Protein Kinase 1 - genetics | Neoplasm Proteins - genetics | Interleukin-6 - metabolism | Cell Survival - drug effects | Drug Screening Assays, Antitumor - methods | Interleukin-6 - genetics | Mitogen-Activated Protein Kinase 3 - genetics | Gene Expression Regulation, Leukemic - drug effects | Pyrimidines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | B-Cell Activating Factor - metabolism | CD40 Ligand - genetics | Mitogen-Activated Protein Kinase 3 - metabolism | Gene Expression Regulation, Enzymologic - genetics | Cell Line, Tumor | Receptors, Antigen, B-Cell - genetics | Mice | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Mitogen-Activated Protein Kinase 1 - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tumor Necrosis Factor-alpha - metabolism | Gene Expression Regulation, Enzymologic - drug effects | Phosphatidylinositol 3-Kinases - metabolism | Gene Expression Regulation, Leukemic - genetics | Protein-Tyrosine Kinases - genetics | CD40 Ligand - metabolism | MAP Kinase Signaling System - genetics | Female | Interleukin-4 - genetics | Protein-Tyrosine Kinases - biosynthesis | Pyrazoles - pharmacology | B-Lymphocytes - enzymology | Neoplasm Proteins - biosynthesis | Interleukin-4 - metabolism | Phosphatidylinositol 3-Kinases - genetics | Animals | MAP Kinase Signaling System - drug effects | NF-kappa B - genetics | B-Cell Activating Factor - genetics | Cell Proliferation - drug effects | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Leukemia, ISSN 0887-6924, 10/2017, Volume 31, Issue 10, pp. 2075 - 2084
Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial... 
MULTICENTER | CLL CELLS | THERAPY | ONCOLOGY | MCL-1 | IBRUTINIB | RESISTANCE | BTK | LYMPHOMA | OPEN-LABEL | HEMATOLOGY | ABT-199 | Peptide Fragments | Pyrazoles - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Pyrazines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - agonists | Neoplasm Proteins - antagonists & inhibitors | Pyrazines - therapeutic use | Molecular Targeted Therapy | Benzamides - administration & dosage | Benzamides - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sulfonamides - agonists | Benzamides - pharmacology | Proto-Oncogene Proteins | Pyrazoles - pharmacology | Pyrimidines - administration & dosage | Bcl-2-Like Protein 11 - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Clinical Trials as Topic | Mitochondria - drug effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bcl-2-Like Protein 11 - biosynthesis | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Protein Kinase Inhibitors - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazines - pharmacology | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Enzymes | Chronic lymphocytic leukemia | Care and treatment | Development and progression | Genetic aspects | Regulation | Drug resistance | Health aspects | Killing | Tyrosine | Drugs | Medical research | Chronic lymphatic leukemia | Bcl-2 protein | Leukemia | Clinical trials | Priming | Lymphatic leukemia | Patients | Bruton's tyrosine kinase | Mitochondria | Inhibitors | Cell death | Sensitivity enhancement | Inhibition | Pretreatment | Protein-tyrosine kinase | BIM protein | Apoptosis | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3734 - 3743
Purpose: Ibrutinib inhibits Bruton tyrosine kinase (BTK) by irreversibly binding to the Cys-481 residue in the enzyme. However, ibrutinib also inhibits several... 
B-CELLS | ACTIVATION | ONCOLOGY | INITIAL THERAPY | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | PCI-32765 | RECEPTOR | OPEN-LABEL | SRC FAMILY KINASES | EXPRESSION | Humans | Pyrazines - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Benzamides - administration & dosage | Protein-Tyrosine Kinases - genetics | T-Lymphocytes - drug effects | Caspase 3 - genetics | Benzamides - adverse effects | Pyrazoles - adverse effects | Pyrimidines - administration & dosage | src-Family Kinases - antagonists & inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Pyrazoles - administration & dosage | Signal Transduction - drug effects | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - adverse effects | Pyrimidines - adverse effects | Cell Line, Tumor | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Poly (ADP-Ribose) Polymerase-1 - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Drugs | Phosphorylation | Leukocyte migration | Downstream effects | Leukemia | Carbon tetrachloride | Homology | Lymphocytes T | Kinases | Caspase-3 | Biological effects | Lymphocytes | Protein-tyrosine kinase | Downstream | Tyrosine | Chronic lymphatic leukemia | Extracellular signal-regulated kinase | Caspase | Poly(ADP-ribose) polymerase | Cultures | CCL3 protein | Lymphatic leukemia | CCL4 protein | Patients | Bruton's tyrosine kinase | Signaling | Inhibitors | Experimental design | Cell death | Cell migration | Chemokines | Cancer | Index Medicus | ibrutinib | apoptosis | Bruton tyrosine kinase | chronic lymphocytic leukemia | acalabrutinib
Journal Article
Bioorganic and Medicinal Chemistry Letters, ISSN 0960-894X, 03/2015, Volume 25, Issue 6, pp. 1333 - 1337
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 10/2017, Volume 140, Issue 4, pp. 985 - 987
Journal Article
Journal Article
Molecular Cancer, ISSN 1476-4598, 12/2018, Volume 17, Issue 1, pp. 1 - 23
Abstract Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and... 
Bruton’s tyrosine kinase | Chronic lymphocytic leukemia | Chemokine receptor | B cell development | B cell receptor signaling | Ibrutinib
Journal Article
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 05/2019, Volume 116, Issue 22, pp. 10798 - 10803
Journal Article
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 05/2019, Volume 116, Issue 19, pp. 9390 - 9399
Bruton's tyrosine kinase (Btk) is critical for B cell proliferation and activation, and the development of Btk inhibitors is a vigorously pursued strategy for... 
BTK FUNCTION | PROTEIN | PHOSPHORYLATION | enhanced sampling | MULTIDISCIPLINARY SCIENCES | dimerization | PH DOMAIN | allosteric activation | Bruton's tyrosine kinase | AUTOINHIBITION | B-CELL | EQUILIBRIUM | DYNAMICS | PIP3 | BINDING | ASSOCIATION | Tyrosine | Molecular dynamics | Phenols | Cell membranes | B cells
Journal Article